ATHE Stock Analysis: Buy, Sell, or Hold?
ATHE - Alterity Therapeutics Limited American Depositary Shares
$3.11
-0.06 (-1.89%)
▼
5d:
-12.89%
30d:
+0.97%
90d:
-32.39%
WAIT
LOW Confidence
Last Updated: February 2, 2026
Get Alerted When ATHE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ATHE is down 12.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ATHE is down 12.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ATHE is currently trading at $3.11, which is considered oversold relative to its 30-day fair value range of $3.14 to $3.45.
Technical Outlook: Technically, ATHE is in a strong downtrend. The price is currently testing key support at $3.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.00 (+285.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATHE is in a strong downtrend. The price is currently testing key support at $3.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.00 (+285.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$3.14 -
$3.45
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 285.9% below Wall St target ($12.00)
- WARNING: Recommendation downgraded due to -12.9% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$3.14 -
$3.45
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$3.03
Resistance Level
$3.84
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-3.94
Wall Street Target
$12.00
(+285.9%)
Revenue Growth (YoY)
80.9%
Profit Margin
-223.3%
Last updated: February 03, 2026 8:41 AM ET
Data refreshes hourly during market hours. Next update: 9:41 AM
Data refreshes hourly during market hours. Next update: 9:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATHE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 61 BUY |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 64 BUY |
